B. Riley Research Analysts Increase Earnings Estimates for TG Therapeutics, Inc. (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Equities researchers at B. Riley boosted their Q2 2024 EPS estimates for shares of TG Therapeutics in a note issued to investors on Tuesday, April 30th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will post earnings of ($0.05) per share for the quarter, up from their previous forecast of ($0.06). B. Riley has a "Buy" rating and a $29.00 price target on the stock. The consensus estimate for TG Therapeutics' current full-year earnings is ($0.11) per share. B. Riley also issued estimates for TG Therapeutics' FY2024 earnings at ($0.14) EPS and FY2025 earnings at $0.78 EPS.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.02). The business had revenue of $63.47 million for the quarter, compared to analyst estimates of $54.60 million. TG Therapeutics had a net margin of 5.42% and a return on equity of 12.89%. TG Therapeutics's revenue for the quarter was up 713.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.28) EPS.

A number of other equities analysts also recently commented on the company. JPMorgan Chase & Co. reiterated an "overweight" rating and issued a $25.00 price target on shares of TG Therapeutics in a research note on Thursday, April 18th. LADENBURG THALM/SH SH boosted their price target on TG Therapeutics from $39.00 to $40.00 and gave the company a "buy" rating in a report on Thursday. StockNews.com lowered shares of TG Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, February 24th. HC Wainwright raised their price target on shares of TG Therapeutics from $45.00 to $49.00 and gave the stock a "buy" rating in a research report on Thursday. Finally, The Goldman Sachs Group boosted their price objective on shares of TG Therapeutics from $12.00 to $13.00 and gave the company a "neutral" rating in a research report on Thursday, February 29th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $29.83.

TG Therapeutics Stock Up 3.4 %

Shares of TGTX stock traded up $0.54 during mid-day trading on Thursday, reaching $16.42. 8,477,473 shares of the company were exchanged, compared to its average volume of 4,335,356. The company has a debt-to-equity ratio of 0.62, a quick ratio of 5.18 and a current ratio of 5.92. The business's 50 day simple moving average is $15.13 and its 200 day simple moving average is $14.33. The company has a market capitalization of $2.54 billion, a P/E ratio of 828.91 and a beta of 2.33. TG Therapeutics has a fifty-two week low of $6.46 and a fifty-two week high of $35.67.

Insiders Place Their Bets

In related news, Director Laurence N. Charney sold 22,000 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total value of $351,340.00. Following the completion of the transaction, the director now directly owns 215,229 shares of the company's stock, valued at approximately $3,437,207.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 9.20% of the stock is owned by insiders.

Institutional Investors Weigh In On TG Therapeutics

Institutional investors have recently bought and sold shares of the stock. New York State Common Retirement Fund raised its position in shares of TG Therapeutics by 1.2% during the 4th quarter. New York State Common Retirement Fund now owns 56,208 shares of the biopharmaceutical company's stock worth $960,000 after buying an additional 663 shares in the last quarter. Kestra Advisory Services LLC boosted its stake in TG Therapeutics by 8.2% during the 3rd quarter. Kestra Advisory Services LLC now owns 16,342 shares of the biopharmaceutical company's stock valued at $137,000 after purchasing an additional 1,240 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of TG Therapeutics by 3.9% during the 1st quarter. Principal Financial Group Inc. now owns 35,374 shares of the biopharmaceutical company's stock valued at $538,000 after purchasing an additional 1,322 shares during the period. Arizona State Retirement System raised its stake in shares of TG Therapeutics by 3.5% in the 3rd quarter. Arizona State Retirement System now owns 40,411 shares of the biopharmaceutical company's stock worth $338,000 after buying an additional 1,356 shares in the last quarter. Finally, Valeo Financial Advisors LLC lifted its holdings in shares of TG Therapeutics by 2.4% in the fourth quarter. Valeo Financial Advisors LLC now owns 63,300 shares of the biopharmaceutical company's stock valued at $1,081,000 after buying an additional 1,500 shares during the period. Institutional investors and hedge funds own 58.58% of the company's stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.